Abstract 369P
Background
More recently, the novel conception of neoadjuvant immunotherapy has generated interest among surgeons worldwide, especially the lack of experience involving surgical treatment for the neoadjuvant immunotherapy population. To address this, the current study was conducted to report the analysis of surgical perspective outcome data after neoadjuvant immunotherapy followed by surgery for resectable non-small-cell lung cancer (NSCLC).
Methods
The current retrospective study was conducted at Shanghai Chest Hospital, an ultra-high-volume tertiary thoracic surgery center in Shanghai, China. Patients with NSCLC, who underwent neoadjuvant immunotherapy or chemo-immunotherapy were retrospectively collected between September 2018 and April 2020. Demographic data, pathologic and clinical features, therapeutic regimens, and outcome data of all individuals were collected by retrospective chart review. Operative details, information of neoadjuvant therapy, were also abstracted.
Results
Of the 14901 patients underwent lung resection in our institute during the study period, 31 patients received neoadjuvant immunotherapy or chemo-immunotherapy for at least 2 courses were included in the study. The patients’ median age was 61 years. 29 of the patients were males while 2 were females. Patients received a median of 3 doses before resection. The median duration from final treatment to surgery was 34 days. After neoadjuvant treatment, post-treatment computed tomography scan showed that 24 patients had partial response. 12 of 31 patients had a major pathologic response, 15 pathologic downstaging. Three patients had no residual viable tumor. A positive surgical margin was identified in 7 cases. One or more postoperative complications occurred in 18 of all 31 patients. 26 of these 31 patients underwent next-generation sequencing (NGS) before surgery in total. Among them, 2 patients (7.7%) were detected STK11 mutations. None of these 2 individuals had an MPR by final pathological examination.
Conclusions
Pulmonary resection after neoadjuvant immunotherapy or chemo-immunotherapy for resectable NSCLC appears to be safe with low operative mortality and morbidity rate in the current population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Natural Science Foundation of China (No. 81702251 and 81972176), the Science Foundation of Shanghai (No.18ZR1435100) and Shanghai Hospital Development Center (SHDC12016113).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
312P - Identification of neoantigen-specific T cell response and anti-tumour immunity in pancreatic cancer
Presenter: Xiaoxiao Du
Session: e-Poster Display Session
313P - Diagnostic value of micro RNA (miRNA) in renal cell cancer: A meta-analysis and systemic review
Presenter: Jestoni Aranilla
Session: e-Poster Display Session
314P - Comprehensive microbial signatures and genomic profiling in tumour samples using next generation sequencing
Presenter: Mei Qi Yee
Session: e-Poster Display Session
315P - High-penetrance breast and/or ovarian cancer susceptibility genes in Filipinos
Presenter: Frances Victoria Que
Session: e-Poster Display Session
316P - Implementation of Vela Analytics to accelerate comprehensive interpretation and reporting of next-generation sequencing-based oncology testing in clinical diagnostic laboratories
Presenter: Yingnan Yu
Session: e-Poster Display Session
317P - Genomic profiling and molecular pathology of Chinese glioma patients
Presenter: yuanli Zhao
Session: e-Poster Display Session
320P - Psychometric interplay of the perception of the real-life impact of COVID-19 pandemic: A cross-sectional survey of patients with newly diagnosed malignancies
Presenter: Kelvin Bao
Session: e-Poster Display Session
321P - Impact of COVID-19 and lockdown on adherence to treatment schedule among cancer patients
Presenter: Krishnamani Kalpathi
Session: e-Poster Display Session
322P - Challenged faced by cancer patients during the COVID-19 pandemic
Presenter: mithra Krishnamani
Session: e-Poster Display Session
323P - Oncology care in the Republic of Kazakhstan during COVID-19
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session